The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Drug repurposing from the perspective of pharmaceutical companies
Open accessAbstract
Drug repurposing holds the potential to bring medications with known safety profiles to new patient populations. Numerous examples exist for the identification of new indications for existing molecules, most stemming from serendipitous findings or focused recent efforts specifically limited to the mode of action of a specific drug. In recent years, the need for new approaches to drug research and development, combined with the advent of big data repositories and associated analytical methods, has generated interest in developing systematic approaches to drug repurposing. A variety of innovative computational methods to enable systematic repurposing screens, experimental as well as through in silico approaches, have emerged. An efficient drug repurposing pipeline requires the combination of access to molecular data, appropriate analytical expertise to enable robust insights, expertise and experimental set‐up for validation and clinical development know‐how. In this review, we describe some of the main approaches to systematic repurposing and discuss the various players in this field and the need for strategic collaborations to increase the likelihood of success in bringing existing molecules to new indications, as well as the current advantages, considerations and challenges in repurposing as a drug development strategy pursued by pharmaceutical companies. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
The ENCODE (ENCyclopedia Of DNA Elements) Project
(2004) · Science · doi:10.1126/science.1105136 · Cited by 2,390
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
A Survey on Wearable Sensor-Based Systems for Health Monitoring and Prognosis
Pantelopoulos, A., & Bourbakis, N. G. (2010) · IEEE Transactions on Systems Man and Cybernetics Part C (Applications and Reviews) · doi:10.1109/tsmcc.2009.2032660 · Cited by 2,296
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
A draft map of the human proteome
Kim, M.-S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., Madugundu, A. K., Kelkar, D. S., Isserlin, R., Jain, S., et al. (2014) · Nature · doi:10.1038/nature13302 · Cited by 2,198
The Meaning of Translational Research and Why It Matters
Woolf, S. H. (2008) · JAMA · doi:10.1001/jama.2007.26 · Cited by 1,910
The NIH Roadmap Epigenomics Mapping Consortium
Bernstein, B. E., Stamatoyannopoulos, J. A., Costello, J. F., Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, M. A., Beaudet, A. L., Ecker, J. R., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1045 · Cited by 1,892
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
von Mering, C. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki005 · Cited by 1,764
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
The SIDER database of drugs and side effects
Kuhn, M., Letunic, I., Jensen, L. J., & Bork, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1075 · Cited by 1,451
Volberding, P. A., Lagakos, S. W., Koch, M. A., Pettinelli, C., Myers, M. W., Booth, D. K., Balfour, H. H., Reichman, R. C., Bartlett, J. A., Hirsch, M. S., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004053221401 · Cited by 1,283
PubChem: Integrated Platform of Small Molecules and Biological Activities
(2008) · Annual Reports in Computational Chemistry · doi:10.1016/s1574-1400(08)00012-1 · Cited by 1,263
Pandey, U. B., & Nichols, C. D. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003293 · Cited by 1,136
DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes
Pinero, J., Queralt-Rosinach, N., Bravo, A., Deu-Pons, J., Bauer-Mehren, A., Baron, M., Sanz, F., & Furlong, L. I. (2015) · Database · doi:10.1093/database/bav028 · Cited by 1,124
The NCBI dbGaP database of genotypes and phenotypes
Mailman, M. D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., Hao, L., Kiang, A., Paschall, J., Phan, L., et al. (2007) · Nature Genetics · doi:10.1038/ng1007-1181 · Cited by 1,105
Southan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035
Correlating chemical sensitivity and basal gene expression reveals mechanism of action
Rees, M. G., Seashore-Ludlow, B., Cheah, J. H., Adams, D. J., Price, E. V., Gill, S., Javaid, S., Coletti, M. E., Jones, V. L., Bodycombe, N. E., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1986 · Cited by 898
PREDICT: a method for inferring novel drug indications with application to personalized medicine
Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.26 · Cited by 881
The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors
Alexander, S. P., Davenport, A. P., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13348 · Cited by 851
Basu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.003 · Cited by 833
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
ImmPort: disseminating data to the public for the future of immunology
Bhattacharya, S., Andorf, S., Gomes, L., Dunn, P., Schaefer, H., Pontius, J., Berger, P., Desborough, V., Smith, T., Campbell, J., et al. (2014) · Immunologic Research · doi:10.1007/s12026-014-8516-1 · Cited by 806
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
DSigDB: drug signatures database for gene set analysis
Yoo, M., Shin, J., Kim, J., Ryall, K. A., Lee, K., Lee, S., Jeon, M., Kang, J., & Tan, A. C. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv313 · Cited by 750
ArrayExpress update—simplifying data submissions
Kolesnikov, N., Hastings, E., Keays, M., Melnichuk, O., Tang, Y. A., Williams, E., Dylag, M., Kurbatova, N., Brandizi, M., Burdett, T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1057 · Cited by 698
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes
Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13354 · Cited by 604
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
Mei, F., Fancy, S. P. J., Shen, Y.-A. A., Niu, J., Zhao, C., Presley, B., Miao, E., Lee, S., Mayoral, S. R., Redmond, S. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3618 · Cited by 590
A regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525 · cited 2×
“…vitro assays is challenged by its validity in presenting the human disease, and an ongoing debate around the use of more representative cell‐based models such as human‐induced pluripotent stem cell‐derived tissues for the case of degenerative diseases is likely to continue (Horvath et al., 2016).”
BackgroundThe discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Akbarian, S., Liu, C., Knowles, J. A., Vaccarino, F. M., Farnham, P. J., Crawford, G. E., Jaffe, A. E., Pinto, D., Dracheva, S., Geschwind, D. H., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4156 · Cited by 451
PharmGKB: the Pharmacogenetics Knowledge Base
Hewett, M. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.163 · Cited by 428
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo
Najm, F. J., Madhavan, M., Zaremba, A., Shick, E., Karl, R. T., Factor, D. C., Miller, T. E., Nevin, Z. S., Kantor, C., Sargent, A., et al. (2015) · Nature · doi:10.1038/nature14335 · Cited by 424
Why Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417 · cited 1×
“Two major apparent categories in drug development can be linked to failure in drug approval, namely, safety and efficacy (Schuster et al., 2005).”
BackgroundUse of genome-wide association studies for drug repositioning
Sanseau, P., Agarwal, P., Barnes, M. R., Pastinen, T., Richards, J. B., Cardon, L. R., & Mooser, V. (2012) · Nature Biotechnology · doi:10.1038/nbt.2151 · Cited by 397
Cowley, G. S., Weir, B. A., Vazquez, F., Tamayo, P., Scott, J. A., Rusin, S., East-Seletsky, A., Ali, L. D., Gerath, W. F., Pantel, S. E., et al. (2014) · Scientific Data · doi:10.1038/sdata.2014.35 · Cited by 387
Annual Reports in Computational Chemistry
(2009) · Annual Reports in Computational Chemistry · doi:10.1016/s1574-1400(09)00513-1 · Cited by 381
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
dbVar and DGVa: public archives for genomic structural variation
Lappalainen, I., Lopez, J., Skipper, L., Hefferon, T., Spalding, J. D., Garner, J., Chen, C., Maguire, M., Corbett, M., Zhou, G., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1213 · Cited by 308
Drug repurposing: far beyond new targets for old drugs
Oprea, T. I., & Mestres, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9390-1 · Cited by 285
Systematic Drug Repositioning Based on Clinical Side-Effects
Yang, L., & Agarwal, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028025 · Cited by 266
The Genotype-Tissue Expression (GTEx) project
Lonsdale, J., Thomas, J., Salvatore, M., Phillips, R., Lo, E., Shad, S., Hasz, R., Walters, G., Garcia, F., Young, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2653 · Cited by 263
Transcriptional data: a new gateway to drug repositioning?
Iorio, F., Rittman, T., Ge, H., Menden, M., & Saez-Rodriguez, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.014 · Cited by 237
PROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
Xu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M., Shah, A., Han, X., Ruan, X., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 218
Xiao, L., Xu, H., Zhang, Y., Wei, Z., He, J., Jiang, W., Li, X., Dyck, L. E., Devon, R. M., Deng, Y., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002064 · Cited by 191
The Comparative Toxicogenomics Database (CTD): a resource for comparative toxicological studies
Mattingly, C. J., Rosenstein, M. C., Colby, G. T., Forrest Jr, J. N., & Boyer, J. L. (2006) · Journal of Experimental Zoology Part A: Comparative Experimental Biology · doi:10.1002/jez.a.307 · Cited by 161
e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design
Pihan, É., Colliandre, L., Guichou, J., & Douguet, D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts186 · Cited by 151
Comprehensive prediction of drug-protein interactions and side effects for the human proteome
Zhou, H., Gao, M., & Skolnick, J. (2015) · Scientific Reports · doi:10.1038/srep11090 · Cited by 138
Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning
Ye, H., Liu, Q., & Jia, W. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087864 · Cited by 130
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
Fransecky, L. R., Mochmann, L. H., & Baldus, C. D. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0040-8 · Cited by 125
Opportunities for drug repositioning from phenome-wide association studies
Rastegar-Mojarad, M., Ye, Z., Kolesar, J., Hebbring, S. J., & Lin, S. M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3183 · Cited by 122
Teachey, D. T., Sheen, C., Hall, J., Ryan, T. M., Brown, V. I., Fish, J. D., Reid, G. S. D., Seif, A. E., Norris, R. E., Chang, Y. J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-137141 · Cited by 122
Brilliant, M. H., Vaziri, K., Connor, T. B., Schwartz, S. G., Carroll, J. J., McCarty, C. A., Schrodi, S. J., Hebbring, S. J., Kishor, K. S., Flynn, H. W., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.015 · Cited by 103
Drug reprofiling using zebrafish identifies novel compounds with potential pro-myelination effects
Buckley, C. E., Marguerie, A., Roach, A. G., Goldsmith, P., Fleming, A., ALDERTON, W. K., & Franklin, R. J. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.014 · Cited by 86
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
Geva, M., Kusko, R. L., Soares, H. D., Fowler, K. D., Birnberg, T., Barash, S., Wagner, A. M., Fine, T., Lysaght, A. C., Weiner, B., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw238 · Cited by 83
Self-citationSetoain, J., Franch, M., Martínez, M., Tabas‐Madrid, D., Sorzano, C. Ó. S., Bakker, A. C., Gonzalez-Couto, E., Elvira, J., & Pascual-Montano, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv445 · Cited by 75
Vidović, D., Koleti, A., & Schürer, S. C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00342 · Cited by 74
Jia, Z., Liu, Y., Guan, N., Bo, X., Luo, Z., & Barnes, M. R. (2016) · BMC Genomics · doi:10.1186/s12864-016-2737-8 · Cited by 72
Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records
Paik, H., Chung, A.-Y., Park, H., Park, R. W., Suk, K., Kim, J., Kim, H., Lee, K., & Butte, A. J. (2015) · Scientific Reports · doi:10.1038/srep08580 · Cited by 66
Lariosa-Willingham, K. D., Rosler, E. S., Tung, J. S., Dugas, J. C., Collins, T. L., & Leonoudakis, D. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2220-2 · Cited by 65
Overcoming obstacles to repurposing for neurodegenerative disease
Shineman, D. W., Alam, J. J., Anderson, M., Black, S. E., Carman, A. J., Cummings, J. L., Dacks, P. A., Dudley, J. T., Frail, D. E., Green, A. M., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.76 · Cited by 60
‘RE:fine drugs’: an interactive dashboard to access drug repurposing opportunities
Moosavinasab, S., Patterson, J., Strouse, R., Rastegar-Mojarad, M., Regan, K., Payne, P., Huang, Y., & Lin, S. M. (2016) · Database · doi:10.1093/database/baw083 · Cited by 60
ksRepo: a generalized platform for computational drug repositioning
Brown, A. S., Kong, S. W., Kohane, I. S., & Patel, C. J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0931-y · Cited by 54
A phenome-guided drug repositioning through a latent variable model
Bişğin, H., Liu, Z., Fang, H., Kelly, R. J., Xu, X., & Tong, W. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-267 · Cited by 50
Tan, F., Yang, R., Xu, X., Chen, X., Wang, Y., Ma, H., Liu, X., Wu, X., Chen, Y., Liu, L., et al. (2014) · Molecular BioSystems · doi:10.1039/c3mb70554d · Cited by 45
Prediction of new drug indications based on clinical data and network modularity
Yu, L., Ma, X., Zhang, L., Zhang, J., & Gao, L. (2016) · Scientific Reports · doi:10.1038/srep32530 · Cited by 42
Global optimization-based inference of chemogenomic features from drug–target interactions
Zu, S., Chen, T., & Li, S. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv181 · Cited by 25
Martorana, A., Perricone, U., & Lauria, A. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160216153457 · Cited by 25
Fowler, K. D., Funt, J. M., Artyomov, M. N., Zeskind, B. J., Kolitz, S. E., & Towfic, F. (2015) · Scientific Reports · doi:10.1038/srep14324 · Cited by 19
Self-citationData integration to prioritize drugs using genomics and curated data
Louhimo, R., Laakso, M., Belitškin, D., Klefström, J. T., Lehtonen, R., & Hautaniemi, S. (2016) · BioData Mining · doi:10.1186/s13040-016-0097-1 · Cited by 17
Cited by
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Blockchain and Artificial Intelligence Technology in E-Health
Tagde, P., Tagde, S., Bhattacharya, T., Tagde, P., Chopra, H., Akter, R., Kaushik, D., & Rahman, M. H. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16223-0 · Cited by 281
Drug repurposing: a systematic review on root causes, barriers and facilitators
Krishnamurthy, N., Grimshaw, A. A., Axson, S. A., Choe, S. H., & Miller, J. E. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08272-z · Cited by 279
Drug Repurposing for Rare Diseases
Roessler, H. I., Knoers, N. V. A. M., van Haelst, M. M., & van Haaften, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.003 · Cited by 269
Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-05323-7 · Cited by 160
Metadata
- Authors
- Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., Papapetropoulos, S., Grossman, I., & Laifenfeld, D.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-05-18
- Volume
- 175
- Issue
- 2
- Pages
- 168-180
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2598265731
- Cited by
- 429
- References
- 83
- FWCI
- 19.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
